The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome

Rheumatology

Volumn 45, Issue 3, 2006, Pages 339-342

  Solau Gervais, E ^a   Soubrier, M ^b   Gerot, I ^a   Grange, L ^c   Puechal, X ^d   Sordet, C ^e   Sibilia, J ^e   Duquesnoy, B ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d CENTRE HOSPITALIER DU MANS   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Bone remodelling markers; Crosslaps; Pamidronate; SAPHO

Indexed keywords

ANALGESIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCALCIN; PAMIDRONIC ACID;

ADULT; ARTICLE; BONE REMODELING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SAPHO SYNDROME; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ACQUIRED HYPEROSTOSIS SYNDROME; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD SEDIMENTATION; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; C-REACTIVE PROTEIN; COLLAGEN; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOCALCIN; PEPTIDE FRAGMENTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33644861045     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei160     Document Type: Article

References (18)

1. Crisp AJ. Pamidronate for SAPHO syndrome. Rheumatology 2003; 42:491.
2. Guignard S, Job-Deslandre C, Sayag-Boukris V, Kahan A. Pamidronate treatment in SAPHO syndrome. Joint Bone Spine 2002;69:392-6.
3. Courtney PA, Hosking DJ, Fairbairn KJ, Deighton CM. Treatment of SAPHO witH pamidronate. Rheumatology 2002;41:1196-8.
4. Kerrison C, Davidson JE, Cleary AG, Beresford MW. Pamidronate in the treatment of childhood SAPHO syndrome. Rheumatology 2004; 43:1246-51.
5. Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A. SAPHO syndrome treated with pamidronate: An open-label study of 10 patients. Rheumatology 2004;43:658-61.
6. Benhamou CL, Chamot AM, Kahn MF. Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A new syndrome among the spondyloarthropathies? Clin Exp Rheumatol 1988; 6:109-12.
7. Hayem G, Bouchaud-Chamot A, Benali K et al. SAPHO syndrome: A long-term follow-up study of 120 cases. Semin Arthritis Rheum 1999;29:159-71.
8. Ballara SC, Siraj QH, Maini RN, Venables PJ. Sustained response to doxycycline therapy in two patients with SAPHO syndrome. Arthritis Rheum 1999;42:819-21.
9. Maksymowych WP, Jhangri GS, Fitzgerald AA et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60mg versus 10mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766-73.
10. Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ. Treatment of fibrous dysplasia of bone with intravenous pamidronate: Long-term effectiveness and evaluation of predictors of response to treatment. Bone 2004,35:235-42.
11. Tucci JR, Bontha S. Intravenously administered pamidronate in the treatment of Paget's disease of bone. Endocr Pract 2001;7:423-9.
12. Marshall H, Bromilow J, Thomas AL, Arden NK. Pamidronate: A novel treatment for the SAPHO syndrome? Rheumatology 2002;41: 231-3.
13. Kopterides P, Pikazis D, Koufos C. Successful treatment of SAPHO syndrome with zoledronic acid. Arthritis Rheum 2004;50:2970-3.
14. Sayag-Boukris V, Loussadi I, Cormier C, Laroche F, Menkes CJ, Kahan A. Efficacy of pamidronate in the treatment of SAPHO syndrome. Arthritis Rheum 1998;41-S114.
15. Acebes C, de la Piedra C, Traba ML et al. Biochemical markers of bone remodeling and bone sialoprotein in ankylosing spondylitis. Clin Chim Acta 1999;289:99-110.
16. Toussirot E, Ricard-Blum S, Dumoulin G, Cedoz JP, Wendling D. Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology 1999; 38:21-7.
17. Rosen HN, Moses AC, Garber J et al. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-3.
18. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6.